A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 115 participants.

Also called NCT01870739

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 115 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01870739
  • EudraCT 2012-005720-15
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Germany, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01870739. Randomized; quadruple masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2015-06 (actual). Results posted on 2016-09-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension
Condition
Hypertension
Intervention (Drug)
sacubitril/valsartan (LCZ696)
Intervention (Drug)
olmesartan
Intervention (Other)
placebo to sacubitril/valsartan (LCZ696)
Intervention (Other)
placebo to olmesartan
Intervention (Drug)
Amlodipine (Optional)
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01870739
Content hash
9e2fb633767ccad211027e1a082be9161aa8e209f42ca007559b32f4c982bb76